Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × bicalutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 115 Breast Neoplasms 10 Neoplasm Metastasis 6 Neoplasms 5 Triple Negative Breast Neoplasms 4 Bulbo-Spinal Atrophy, X-Linked 4 Salivary Gland Neoplasms 2 Osteoporosis 2 Lower Urinary Tract Symptoms 2 Hirsutism 2 Thrombocytosis 1 Stage I Prostate Adenocarcinoma AJCC v7 1 Stage I Prostate Adenocarcinoma 1 Sexual Dysfunction, Physiological 1 Recurrence 1 Prostate Adenocarcinoma 1 Primary Myelofibrosis 1 Primary Dysautonomias 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Paget Disease, Extramammary 1 PSA Level Greater Than Two 1 Ovarian Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Non Castrate Metastatic Prostate Cancer 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1

Interventions

pembrolizumab 70 Gemcitabine 44 Nivolumab 36 Cisplatin 32 atezolizumab 31 Carboplatin 25 avelumab 24 enfortumab vedotin 21 Docetaxel 20 Magnetic Resonance Spectroscopy 16 Mitomycin 14 Ipilimumab 14 Paclitaxel 13 Specimen Handling 11 durvalumab 10 toripalimab 8 sacituzumab govitecan 8 vinflunine 7 cabozantinib 7 Pemetrexed 7 Injections 6 Cyclophosphamide 6 Bevacizumab 6 tislelizumab 5 pemigatinib 5 Taxes 5 Fluorodeoxyglucose F18 5 Biopsy 5 lenvatinib 4 fludarabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06018116 2024-02-15

CANUCK-01

CHU de Quebec-Universite Laval

Phase 2 Withdrawn

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡